Agendia BV, a Dutch developer of molecular diagnostic services for oncology research, has raised EUR 25 million ($34m) in fourth-round funding. ING was joined by return backers Van Herk Biotech, Gilde Healthcare Partners and Global Life Science Ventures. The company has not disclosed financial information for its prior funding rounds. www.agendia.com